Abstract 445P
Background
Nasopharyngeal cancer (NPC) is notably prevalent in Southeast Asia, including Hong Kong. The survival rate of NPC patients has improved over the past decade. However, the emergence of various late radiation side effects during survivorship remains a concern. While the clinician-reported incidence of symptoms has been reported, a comprehensive assessment of self-reported symptoms is still lacking. This study aims to examine the subjective symptom burden, quality of life, and unmet needs among local NPC survivors.
Methods
A single-centre cross-sectional survey was conducted at a local public hospital, including 200 NPC survivors who had completed radiation therapy (RT) with or without chemotherapy for three to 120 months. We employed the Chinese version of three questionnaires: M. D. Anderson Symptom Inventory - Head & Neck Module (MDASI-HN), Functional Assessment of Cancer Therapy - Head & Neck (FACT-HN), and Cancer Survivors’ Unmet Needs Measure (CaSUN).
Results
Survivors experienced, on average, more than four moderate to severe symptoms (Mean [M] ± SD = 4.84±4.99), with no association found with post-RT time (p = 0.443). The top five severe symptoms were dry mouth (M±SD = 5.47±2.90), mucus problem (M±SD = 4.27±3.17), dysphagia (M±SD = 3.38±3.03), teeth/gum problems (M±SD = 2.98±3.17), and poor memory (M±SD = 2.94±2.63). The mean scores of the top five symptoms were used to represent the symptom burden, which was negatively associated with the physical (F(1,198) = 139.783, p < 0.001, R2 = 0.414), emotional (F(2,197) = 38.303, p < 0.001, R2 = 0.280), additional concerns (F(1,198) = 85.993, p < 0.001, R2 = 0.303) subscales, and the total scores (F(2,197) = 33.083, p < 0.001, R2 = 0.251) of the FACT-HN. The unmet need for symptom management by CaSUN was positively associated with symptom burden (OR = 1.379, 95% CI [1.185, 1.604], p < 0.001), while negatively associated with post-RT time (OR = 0.981, 95% CI [0.972, 0.991], p < 0.001).
Conclusions
NPC survivors suffer from symptoms irrespective of the time elapsed post-RT. The observed varying unmet need for symptom management necessitates further exploration into supportive care for cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract